Wedbush increased its price target for Ascendis Pharma to $346, up from $327.

ASND · Ascendis Pharma

The AI's read

This adds a favorable outside view of Ascendis Pharma, but says nothing about sales, trial results, or profit. The article gives no figures from the recent quarterly report, so the raised target and maintained rating—not new company results—drive the positive reading.